Obinutuzumab versus rituximab-based chemotherapy in high-tumor burden indolent B-cell lymphoma: a real-world comparative study.

89.8%), the difference did not reach statistical significance (p=0.1) ( Figure 3B ), likely reflecting the relatively short follow-up duration and the overall favorable prognosis of FL, which may limit the power to detect OS differences in this subgroup analysis. 3.5.2 Marginal zone lymphoma subgroup (n=71) The MZL subgroup included 26 patients with splenic MZL (SMZL), 27 with mucosa-associated lymphoid tissue (MALT) lymphoma, and 18 with nodal MZL (NMZL).

also in 111,027 other papers